Evaluating the Bioequivalence of Antibody–Drug Conjugates - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Evaluating the Bioequivalence of Antibody–Drug Conjugates
The authors discuss the analytical methods and related testing for bioequivalence studies of ADCs. This article is part of a special issue on analytical technology.

Pharmaceutical Technology
pp. s22-s27

Analytical methods for bioequivalence studies

Table I. Analytical technologies for assessment of biologics.
Analytical-method development for biologics usually starts with establishing a suitable manufacturing process, followed by the development of analytical methods intended to confirm adequate structural and functional comparison with the target product profile (i.e., for ADCs, the starting mAb). The regulatory guidelines about this development require an understanding of the molecular structure, glycol microheterogeneity profile, impurities, degradation products, and bioavailability, as shown in Table I (13–16).

The normal complexity in evaluating lot-to-lot variation and its implications is further compounded because each of the three major components (mAb, linker, and cytotoxin) must be fully characterized. According to EMA's biosimilar guidelines, "Every mAb is unique and small structural changes can have significant functional consequences since even the same expression system and similar culture conditions might lead to a distinct product profile (e.g., impurities and microheterogeneity)" (14). Manufacturing modifications or synthetic-process changes may require further nonclinical and clinical studies.

The structural integrity of ADCs is evaluated using techniques such as amino acid sequencing (N- or C- terminal), biochemical testing, carbohydrate mapping, high-performance liquid chromatography (HPLC), electrophoresis (i.e., sodium dodecyl sulfate polyacrylamide gel electrophoresis [SDS-PAGE], isoelectric focusing [IEF], and Western blotting), immunoassays (enzyme-linked immunosorbent assay [ELISA] and Gyros), macromolecular liquid chromatography–mass spectrometry (MS)/MS (LC–MS/MS), nuclear magnetic resonance (NMR) spectroscopy, optical spectroscopy, X-ray crystallography, peptide mapping, ultracentrifugation, and other physiochemical methods to show that the purified mAb is not fragmented, aggregated, or otherwise modified. Specificity characterization can be performed using in vitro cell-based assays or in vivo animal models and should provide evidence that the ADC is specific for its intended target and has low cross-reactivity with human tissues. Potency characterization is used for assessment of lot-to-lot consistency and stability and may involve techniques, such as ELISA, Gyros, flow cytometry, cytotoxicity, and animal models.

Most mAbs are produced in bioreactors, so DNA, RNA, viral burden, host-cell protein, endotoxins/pyrogenicity, and growth-media components all must be monitored and controlled in the final ADC product. mAbs are glycosylated proteins composed of four peptide chains connected by disulfide bridges. The oligosaccharide residues on mAbs may be involved in activity, and, therefore, mAbs should be characterized for protein, peptide sequence, glycoprotein, and oligosaccharide content. The binding activity, affinity, avidity, immunoreactivity, source of all materials, chemical structures and production processes, purity, viral load, and the average mAb-to-drug ratio all must be clearly defined. Contaminants and impurities must be carefully controlled, monitored, and minimized. Stability should be carefully monitored for intact ADC and bioactivity. Immunogenicity is a major concern for nonhumanized mAbs and must be thoroughly evaluated (16). Bioavailability, receptor binding, stability, and immunogenicity are major issues of pharmaceutical equivalence for ADCs.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here